Loading…
Loading…
VYYRF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VYYRF and 80,000+ other tickers.
See exactly how VYYRF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VYYRF and 80,000+ other tickers.
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations…
CALGARY, Alberta – August 10, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to provide an update on the advancement of its proprietary patent-pending Mueller iodine extraction process. The Mueller process is being developed to recover high-purity iodine from iodine-rich oilfield brine, supporting Voyageur's strategy to establish a domestic iodine supply for the North American radiology contrast media market, while offering oil and gas producers and midstream water operators a new pathway to generate value from produced brine. Recent laboratory work has successfully produced iodine at 99.8% purity, with overall process recovery exceeding 90%.
Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization and liquidity services to the Company in compliance with the policies and guidelines of the TSXV and other applicable legislation, pursuant to letter of engagement entered into between the Company and Red Cloud effective July 14, 2026 (the "Agreement").
CALGARY, Alberta – TheNewswire - June 23, 2026 – Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Fluor Corporation (“ Fluor ”), a leading global engineering, procurement, construction and maintenance firm, to complete comprehensive feasibility studies for two strategic projects that will advance the Company's vertically integrated North American supply chain for radiology contrast drugs. The engagement covers:
CALGARY, Alberta – June 18, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility. The Company is completing a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites. Key evaluation criteria include proximity to iodine brine sources (expected to support an estimated +70% of future revenue), logistics, infrastructure, access to skilled labour, and the strength of government incentive packages. Voyageur is actively engaging with economic development authorities across multiple U.S. jurisdictions. The final site will be selected based on the most attractive overall combination of factors, with a strong emphasis on the incentive and support packages offered. This competitive process is designed to optimize project economics and accelerate development timelines.
Calgary, Alberta – TheNewswire - June 10, 2026 – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur ") announces the submission of a Multi-Year Area-Based (" MYAB ") Notice of Work (" NoW ") application to the British Columbia Ministry of Mining and Critical Minerals for its Frances Creek barite project. The application seeks authorization for a five-year advanced exploration program on a 76.8-hectare work area within mineral claims 571267, 1054177, and 1031568. The proposed program includes exploration trenching, access trail development, construction of a processing area, and development of a mine rock storage facility (MRSF), all located primarily on previously disturbed forestry land. A comprehensive package of technical studies was submitted with the application, including terrain stability assessment and trench/MRSF design, acid rock drainage and metal leachate assessment, soil surveys, archaeological assessment, and management plans for dust, weeds, and emergency response.